PHASE Scientific has raised $34 million in Series A funding to advance its urine-based diagnostic technology, with a significant focus on women’s health applications including HPV and cervical cancer screening. The round was led by Value Partners Group with participation from various other healthcare-focused investors.
The company plans to use the funds to accelerate R&D and commercialization of its PHASIFY urine concentration technology, which captures approximately ten times more biomarkers than current industry standards, according to the company. PHASE Scientific has already developed a urine-based HPV test, potentially transforming cervical cancer screening by making it more accessible and comfortable. In a recent clinical study with Peking University Shenzhen Hospital, the test demonstrated 93.4% sensitivity in detecting CIN2+ lesions (cervical precancer and cancer) and over 97% concordance with the gold-standard physician-collected testing for HPV types 16 and 18.
“The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection,” said Dr. Ricky Chiu, Founder, Chairman and CEO of PHASE Scientific. “With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market.”
Traditional cervical cancer screening methods can be invasive, uncomfortable, and require clinical visits, creating barriers to regular testing. PHASIFY technology enables at-home sample collection through urine, potentially increasing screening rates and earlier detection of HPV infections that could lead to cervical cancer.
Beyond HPV testing, PHASE Scientific is developing additional women’s health diagnostics using its urine concentration platform. The company has already launched over 30 diagnostic products across multiple health categories and distributed more than 100 million tests in over 30 countries.
“We are delighted to become a partner of PHASE Scientific as it rapidly grows and addresses critical unmet needs in early disease detection,” said Dr. Chuen Yan Leung, Partner at Value Partners Group. “Its innovative technology represents a paradigm shift, offering an unparalleled combination of clinical precision and patient-centric solutions.”
Founded in 2015, PHASE Scientific operates across Hong Kong, Southern California, and China’s Greater Bay Area.
